Who are Magnogene ® (magnesium)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): potassium chloride replacement, Balance Tablet, Calcium carbonate tablets, intraperitoneal nebulisation of magnesium sulphate, Magnesium glycinate, Two policies of iron prophylaxis.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/magnogene-magnesium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Magnogene ® (magnesium) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Magnogene ® (magnesium) (Magnogene ® (magnesium)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mineral supplement. Area: Nutritional/Metabolic.

marketed Mineral supplement Magnesium ion (Mg2+) Nutritional/Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Magnogene ® (magnesium) (Magnogene ® (magnesium)) — University Hospital, Clermont-Ferrand. Magnogene is a magnesium supplement that replaces or maintains magnesium levels in the body to support enzymatic function, muscle and nerve function, and metabolic processes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Magnogene ® (magnesium) TARGET	Magnogene ® (magnesium)	University Hospital, Clermont-Ferrand	marketed	Mineral supplement	Magnesium ion (Mg2+)
potassium chloride replacement	potassium chloride replacement	Baptist Health South Florida	marketed	Electrolyte replacement / mineral supplement	Potassium ion (K+)
Balance Tablet	Balance Tablet	General Committee of Teaching Hospitals and Institutes, Egypt	marketed	Electrolyte/mineral supplement
Calcium carbonate tablets	Calcium carbonate tablets	Chinese SLE Treatment And Research Group	marketed	Mineral supplement / Calcium salt
intraperitoneal nebulisation of magnesium sulphate	intraperitoneal nebulisation of magnesium sulphate	B.P. Koirala Institute of Health Sciences	marketed	Mineral supplement / Anti-inflammatory agent	NMDA receptor (indirect antagonism); local anti-inflammatory pathways
Magnesium glycinate	Magnesium glycinate	CMH Kharian Medical College	marketed	Mineral supplement / Nutritional supplement
Two policies of iron prophylaxis	Two policies of iron prophylaxis	National Istitute For Health and Welfare, Finland	marketed	Mineral supplement / Nutritional agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mineral supplement class)

Gerencia de Atención Primaria, Albacete · 1 drug in this class
Sanofi · 1 drug in this class
University Hospital, Clermont-Ferrand · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Magnogene ® (magnesium) — Competitive Intelligence Brief. https://druglandscape.com/ci/magnogene-magnesium. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing